Jenburkt Pharmaceuticals

₹974.00As of Sun 8 Nov 2026, 12:00 UTC

NSE:JENBURPH—

Country India

PE (Fwd) 10.81

TSR 10Y CAGR —

Div yield 2.13%

ROE —

Pharmaceutical Preparations

Beta (5Y) 0.40

PE TTM 12.37

TSR TTM —

Mkt cap ₹4.236B

ROIC —

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

₹1,043

—

7.10%

—

—

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

5Y

10Y

Peers

1.687

Revenue₹B

—

—

—

—

—

1.240

1.367

1.420

1.517

1.687

1.808

8.01%

8.01%

28

11.24

Revenue growth%

—

—

—

—

—

—

10.30

3.82

6.85

11.24

7.17

8.57

—

44

79.98

Gross margin%

—

—

—

—

—

74.07

75.24

77.92

79.68

79.98

80.02

77.92

77.92

96

25.19

Operating margin%

—

—

—

—

—

20.52

20.61

21.68

24.84

25.19

25.19

21.68

21.68

96

20.59

Net margin%

—

—

—

—

—

17.98

17.99

18.30

21.14

20.59

20.59

18.30

18.30

96

12.37

P/E ratio (avg)x

—

—

—

—

—

—

—

—

—

—

11.55

—

—

37

10.11

EV/EBITx

—

—

—

—

—

—

—

—

—

—

9.436

—

—

70

—

FCF yield (avg)%

—

—

—

—

—

—

—

—

—

—

—

—

—

52

—

FCF margin%

—

—

—

—

—

—

—

—

—

—

—

—

—

72

—

FCF / Net incomex

—

—

—

—

—

—

—

—

—

—

—

—

—

37

—

ROIC%

—

—

—

—

—

—

—

—

—

—

—

—

—

96

—

Return on equity%

—

—

—

—

—

—

—

—

—

—

—

—

—

81

—

Return on assets%

—

—

—

—

—

—

—

—

—

—

—

—

—

96

78.71

EPS₹

—

—

—

—

—

48.58

53.90

58.86

72.65

78.71

84.35

12.82%

12.82%

—

8.34

EPS growth%

—

—

—

—

—

—

10.93

9.21

23.42

8.34

7.17

10.07

—

39

—

Bookvalue per sh₹

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

FCF per share₹

—

—

—

—

—

—

—

—

—

—

—

—

—

—

20.70

Dividend per sh₹

—

—

—

—

—

12.00

14.40

15.30

18.00

20.70

21.89

14.60%

14.60%

—

2.13

Div yield (avg)%

—

—

—

—

—

—

—

—

—

—

2.25

—

—

50

26.30

Payout ratio%

—

—

—

—

—

24.70

26.72

25.99

24.78

26.30

25.95

25.99

25.99

50

4.413

Shares (diluted)M

—

—

—

—

—

4.589

4.566

4.413

4.413

4.413

◌4.413

(0.97%)

(0.97%)

76

—

Buyback yield%

—

—

—

—

—

—

0.52

3.34

—

—

◌—

0.26

—

76

—

D/E ratiox

—

—

—

—

—

—

—

—

—

—

—

—

—

78

4.299

Enterprise value₹B

—

—

—

—

—

—

—

—

—

—

4.299

—

—

32

—

LT debt₹M

—

—

—

—

—

—

—

—

—

—

—

—

—

22

Peers (US$44.32M)

Cap (US$)

PE

Trident Lifeline…

52.57M

21.04x

Astonea Labs Limited

37.50M

74.64x

Ambalal Sarabhai…

28.77M

18.26x

Samik Pharmaceutical…

44.16M

—

Capital

TTM

5Y

10Y

Leveragex

—

—

—

EBIT/Intx

114.3

99.13

99.13

Own earn%

—

—

—

Sh yield%

2.13

0.26

0.26

Owners

Insiders/Inst%

55.12

6.30

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

4/4

EPS growth years

4/4

Dividend streakyrs

0

Op margin range%

21–25

$1 testx

—

Incr. ROIC%

—

Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations in India and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹1.687B

8.01%

1.00×

Cost of revenue

₹337.8M

1.25%

0.77×

Operating expenses

₹924.5M

8.63%

1.02×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

-

Return on capital

n/m

-

Spread over hurdle

n/m

-